JP2004521908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521908A5 JP2004521908A5 JP2002564526A JP2002564526A JP2004521908A5 JP 2004521908 A5 JP2004521908 A5 JP 2004521908A5 JP 2002564526 A JP2002564526 A JP 2002564526A JP 2002564526 A JP2002564526 A JP 2002564526A JP 2004521908 A5 JP2004521908 A5 JP 2004521908A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- formula
- group
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 93
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 51
- 229910052717 sulfur Inorganic materials 0.000 claims 38
- 125000004430 oxygen atom Chemical group O* 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 35
- 229910052757 nitrogen Inorganic materials 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 24
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 21
- 239000001301 oxygen Substances 0.000 claims 21
- 239000011593 sulfur Chemical group 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical class 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 19
- 125000004432 carbon atom Chemical group C* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 125000004434 sulfur atom Chemical group 0.000 claims 16
- 150000001204 N-oxides Chemical class 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- -1 2,1,3-benzothiadiazolyl Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 7
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 7
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 claims 7
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 7
- 125000002541 furyl group Chemical group 0.000 claims 7
- 125000002883 imidazolyl group Chemical group 0.000 claims 7
- 125000001041 indolyl group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000001544 thienyl group Chemical group 0.000 claims 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- BOAPXJJSGBQJPM-UHFFFAOYSA-N 4-[[7-[(4-fluorophenyl)methylcarbamoyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(C(=O)NCC=3C=CC(F)=CC=3)=CC=C2N2C=NN=C21 BOAPXJJSGBQJPM-UHFFFAOYSA-N 0.000 claims 3
- FAUYRBMJEJPIBN-UHFFFAOYSA-N C1=NN=C2N1C1=CC=C(C=C1C=N2)C(=O)N Chemical compound C1=NN=C2N1C1=CC=C(C=C1C=N2)C(=O)N FAUYRBMJEJPIBN-UHFFFAOYSA-N 0.000 claims 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 3
- 229940095102 methyl benzoate Drugs 0.000 claims 3
- XVEUJJPWIBJRKG-UHFFFAOYSA-N 2-[4-[[7-(1,3-benzodioxol-5-ylmethylcarbamoyl)-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CN1C(=O)C2=CC(C(=O)NCC=3C=C4OCOC4=CC=3)=CC=C2N2C=NN=C21 XVEUJJPWIBJRKG-UHFFFAOYSA-N 0.000 claims 2
- VMSPJYJGWZXQDC-UHFFFAOYSA-N 2-[4-[[7-[(4-methoxyphenyl)methylcarbamoyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C2N3C=NN=C3N(CC=3C=CC(CC(O)=O)=CC=3)C(=O)C2=C1 VMSPJYJGWZXQDC-UHFFFAOYSA-N 0.000 claims 2
- SZTKBYYYFKIGFX-UHFFFAOYSA-N 2-[4-[[7-[methyl(pyridin-4-yl)carbamoyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]phenyl]acetic acid Chemical compound C=1C=NC=CC=1N(C)C(=O)C(C=1)=CC=C(N2C=NN=C22)C=1C(=O)N2CC1=CC=C(CC(O)=O)C=C1 SZTKBYYYFKIGFX-UHFFFAOYSA-N 0.000 claims 2
- XPEBEBAMQSQWRR-UHFFFAOYSA-N 4-[[4-(dimethylcarbamoyl)phenyl]methyl]-n-[(4-methoxyphenyl)methyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C2N3C=NN=C3N(CC=3C=CC(=CC=3)C(=O)N(C)C)C(=O)C2=C1 XPEBEBAMQSQWRR-UHFFFAOYSA-N 0.000 claims 2
- FRYLUMQFQIKBLA-UHFFFAOYSA-N 4-[[5-oxo-7-(pyridin-4-ylmethylcarbamoyl)-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(C(=O)NCC=3C=CN=CC=3)=CC=C2N2C=NN=C21 FRYLUMQFQIKBLA-UHFFFAOYSA-N 0.000 claims 2
- ACOPHWCAIPSBOT-UHFFFAOYSA-N 4-[[7-(1,3-benzodioxol-5-ylmethylcarbamoyl)-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(C(=O)NCC=3C=C4OCOC4=CC=3)=CC=C2N2C=NN=C21 ACOPHWCAIPSBOT-UHFFFAOYSA-N 0.000 claims 2
- AHQAOXKCZQNXHU-UHFFFAOYSA-N 4-[[7-[(4-methoxyphenyl)methylcarbamoyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C2N3C=NN=C3N(CC=3C=CC(=CC=3)C(O)=O)C(=O)C2=C1 AHQAOXKCZQNXHU-UHFFFAOYSA-N 0.000 claims 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 2
- KYMITHWDCVDTJI-UHFFFAOYSA-N C(C)(=O)OCC1=CC=C(C=C1)CN1C=2N(C3=CC=C(C=C3C1=O)C(NCC1=CC3=C(OCO3)C=C1)=O)C=NN2 Chemical compound C(C)(=O)OCC1=CC=C(C=C1)CN1C=2N(C3=CC=C(C=C3C1=O)C(NCC1=CC3=C(OCO3)C=C1)=O)C=NN2 KYMITHWDCVDTJI-UHFFFAOYSA-N 0.000 claims 2
- HGFMWNVYEIWJCZ-UHFFFAOYSA-N C(C)(=O)OCC1=CC=C(C=C1)CN1C=2N(C3=CC=C(C=C3C1=O)C(NCC1=CC=C(C=C1)OC)=O)C=NN2 Chemical compound C(C)(=O)OCC1=CC=C(C=C1)CN1C=2N(C3=CC=C(C=C3C1=O)C(NCC1=CC=C(C=C1)OC)=O)C=NN2 HGFMWNVYEIWJCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- BQNPWAAFQUWJQO-UHFFFAOYSA-N benzyl 4-benzyl-5-oxo-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxylate Chemical compound C=1C=C(N2C=NN=C2N(CC=2C=CC=CC=2)C2=O)C2=CC=1C(=O)OCC1=CC=CC=C1 BQNPWAAFQUWJQO-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- DFZBQXFAFJIXHG-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-4-[(4-cyanophenyl)methyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C=1C=C2OCOC2=CC=1CNC(=O)C(C=1)=CC=C(N2C=NN=C22)C=1C(=O)N2CC1=CC=C(C#N)C=C1 DFZBQXFAFJIXHG-UHFFFAOYSA-N 0.000 claims 2
- FMJHCLBRSAPIGN-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-4-benzyl-5-oxo-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C=1C=C2OCOC2=CC=1CNC(=O)C(C=1)=CC=C(N2C=NN=C22)C=1C(=O)N2CC1=CC=CC=C1 FMJHCLBRSAPIGN-UHFFFAOYSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- WQDWXMNOPFULEC-UHFFFAOYSA-N pyridin-4-ylmethyl 4-benzyl-5-oxo-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxylate Chemical compound C=1C=C(N2C=NN=C2N(CC=2C=CC=CC=2)C2=O)C2=CC=1C(=O)OCC1=CC=NC=C1 WQDWXMNOPFULEC-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- CKDZEXUCUNHQIY-UHFFFAOYSA-N 2h-tetrazole-5-carbonitrile Chemical compound N#CC=1N=NNN=1 CKDZEXUCUNHQIY-UHFFFAOYSA-N 0.000 claims 1
- QZJZINZWIMVODU-UHFFFAOYSA-N 4-[(4-cyanophenyl)methyl]-5-oxo-n-(pyridin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C=1C=C(N2C=NN=C2N(CC=2C=CC(=CC=2)C#N)C2=O)C2=CC=1C(=O)NCC1=CC=NC=C1 QZJZINZWIMVODU-UHFFFAOYSA-N 0.000 claims 1
- HKBRYGMHTOURBK-UHFFFAOYSA-N 4-[2-(4-chlorophenoxy)ethyl]-n-[(4-methoxyphenyl)methyl]-5-oxo-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C2N3C=NN=C3N(CCOC=3C=CC(Cl)=CC=3)C(=O)C2=C1 HKBRYGMHTOURBK-UHFFFAOYSA-N 0.000 claims 1
- MLLSAERKYCNOKU-UHFFFAOYSA-N 4-benzyl-5-oxo-n-(pyridin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C=1C=C(N2C=NN=C2N(CC=2C=CC=CC=2)C2=O)C2=CC=1C(=O)NCC1=CC=NC=C1 MLLSAERKYCNOKU-UHFFFAOYSA-N 0.000 claims 1
- AXIMIOFWLRUQPQ-UHFFFAOYSA-N 4-benzyl-5-oxo-n-(pyridin-4-ylmethyl)imidazo[1,2-a]quinazoline-7-carboxamide Chemical compound C=1C=C(N2C=CN=C2N(CC=2C=CC=CC=2)C2=O)C2=CC=1C(=O)NCC1=CC=NC=C1 AXIMIOFWLRUQPQ-UHFFFAOYSA-N 0.000 claims 1
- QINLAXZPVOGUSR-UHFFFAOYSA-N 5-oxo-n-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylprop-2-enyl)-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxamide Chemical compound C=1C=C(N2C=NN=C2N(CC=CC=2C=CN=CC=2)C2=O)C2=CC=1C(=O)NCC1=CC=NC=C1 QINLAXZPVOGUSR-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- MNDSJWSNYDGKEK-UHFFFAOYSA-N C(C)(=O)OCC1=CC=C(C=C1)CN1C=2N(C3=CC=C(C=C3C1=O)C(N(C)C1=CC=NC=C1)=O)C=NN2 Chemical compound C(C)(=O)OCC1=CC=C(C=C1)CN1C=2N(C3=CC=C(C=C3C1=O)C(N(C)C1=CC=NC=C1)=O)C=NN2 MNDSJWSNYDGKEK-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000012024 dehydrating agents Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- FMJDKOBXRJYZKD-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-4-benzyl-5-oxoimidazo[1,2-a]quinazoline-7-carboxamide Chemical compound C=1C=C2OCOC2=CC=1CNC(=O)C(C=1)=CC=C(N2C=CN=C22)C=1C(=O)N2CC1=CC=CC=C1 FMJDKOBXRJYZKD-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26875701P | 2001-02-14 | 2001-02-14 | |
| PCT/EP2002/001961 WO2002064595A1 (en) | 2001-02-14 | 2002-02-11 | Triazolo compounds as mmp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521908A JP2004521908A (ja) | 2004-07-22 |
| JP2004521908A5 true JP2004521908A5 (enExample) | 2005-08-04 |
Family
ID=23024335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564526A Abandoned JP2004521908A (ja) | 2001-02-14 | 2002-02-11 | Ｍｍｐ阻害剤としてのトリアゾロ化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6849637B2 (enExample) |
| EP (1) | EP1362048B1 (enExample) |
| JP (1) | JP2004521908A (enExample) |
| AR (1) | AR032677A1 (enExample) |
| AT (1) | ATE294805T1 (enExample) |
| BR (1) | BR0207270A (enExample) |
| CA (1) | CA2437588A1 (enExample) |
| DE (1) | DE60203995T2 (enExample) |
| ES (1) | ES2239216T3 (enExample) |
| HN (1) | HN2002000038A (enExample) |
| MX (1) | MXPA03007249A (enExample) |
| PA (1) | PA8539501A1 (enExample) |
| PE (1) | PE20020885A1 (enExample) |
| SV (1) | SV2002000875A (enExample) |
| WO (1) | WO2002064595A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| WO2002064598A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| EP1434585A1 (en) | 2001-10-12 | 2004-07-07 | Warner-Lambert Company LLC | Alkyne matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| JP2006503811A (ja) * | 2002-07-17 | 2006-02-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ |
| BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
| MXPA05000476A (es) * | 2002-07-17 | 2005-03-23 | Warner Lambert Co | Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
| JP2006502992A (ja) * | 2002-07-17 | 2006-01-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ−１３のアロステリック阻害剤とセレコキシブ又はバルデコキシブとの組合せ |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| EP1537090A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| WO2004014354A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| JP2006500350A (ja) * | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのイソキノリン誘導体 |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| WO2004014866A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004014365A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| JP2006500351A (ja) | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体 |
| WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| BR0313459A (pt) | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| EP1680125A1 (en) * | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| WO2006128184A2 (en) * | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| US7795877B2 (en) * | 2006-11-02 | 2010-09-14 | Current Technologies, Llc | Power line communication and power distribution parameter measurement system and method |
| US20080176870A1 (en) * | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| DE102010031945A1 (de) * | 2010-07-22 | 2012-01-26 | Osram Opto Semiconductors Gmbh | Halbleiterbauelement und Verfahren zur Herstellung eines Halbleiterbauelements |
| DK2663309T3 (en) | 2011-01-10 | 2017-06-19 | Infinity Pharmaceuticals Inc | METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| IL263680B2 (en) | 2016-06-24 | 2025-10-01 | Infinity Pharmaceuticals Inc | PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer |
| CN115197225B (zh) * | 2021-09-03 | 2023-04-11 | 贵州大学 | 一种五元杂环并喹唑啉酮类化合物及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455311A (en) * | 1981-08-28 | 1984-06-19 | Hoffmann-La Roche Inc. | Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system |
| IL66835A (en) * | 1981-09-24 | 1988-05-31 | Roussel Uclaf | 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them |
| DE3677445D1 (de) * | 1985-09-30 | 1991-03-14 | Ciba Geigy Ag | 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung. |
| US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| CA2263886A1 (en) | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用 |
| UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
| FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
| PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| WO2002034726A2 (en) | 2000-10-26 | 2002-05-02 | Pfizer Products Inc. | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| WO2002034753A2 (en) | 2000-10-26 | 2002-05-02 | Pfizer Products Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| BR0213239A (pt) | 2001-10-12 | 2004-09-28 | Warner Lambert Co | Compostos de pirimidina com anel condensado alcinilado como inibidores da metalo-proteinase da matriz de tipo 13 |
| US6962922B2 (en) * | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| EP1434585A1 (en) * | 2001-10-12 | 2004-07-07 | Warner-Lambert Company LLC | Alkyne matrix metalloproteinase inhibitors |
| WO2003076416A1 (en) | 2002-03-08 | 2003-09-18 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
| US6747147B2 (en) * | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6894057B2 (en) * | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| WO2004000321A1 (en) | 2002-06-25 | 2003-12-31 | Warner-Lambert Company Llc | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| WO2004014384A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
-
2002
- 2002-02-08 PA PA20028539501A patent/PA8539501A1/es unknown
- 2002-02-11 BR BR0207270-0A patent/BR0207270A/pt not_active IP Right Cessation
- 2002-02-11 EP EP02702366A patent/EP1362048B1/en not_active Expired - Lifetime
- 2002-02-11 CA CA002437588A patent/CA2437588A1/en not_active Abandoned
- 2002-02-11 MX MXPA03007249A patent/MXPA03007249A/es unknown
- 2002-02-11 DE DE60203995T patent/DE60203995T2/de not_active Expired - Fee Related
- 2002-02-11 AT AT02702366T patent/ATE294805T1/de not_active IP Right Cessation
- 2002-02-11 WO PCT/EP2002/001961 patent/WO2002064595A1/en not_active Ceased
- 2002-02-11 ES ES02702366T patent/ES2239216T3/es not_active Expired - Lifetime
- 2002-02-11 JP JP2002564526A patent/JP2004521908A/ja not_active Abandoned
- 2002-02-13 HN HN2002000038A patent/HN2002000038A/es unknown
- 2002-02-13 PE PE2002000115A patent/PE20020885A1/es not_active Application Discontinuation
- 2002-02-13 SV SV2002000875A patent/SV2002000875A/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100471A patent/AR032677A1/es not_active Application Discontinuation
- 2002-02-14 US US10/075,654 patent/US6849637B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521908A5 (enExample) | ||
| EP2560966B1 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
| RU2205827C2 (ru) | Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция | |
| RU2310648C2 (ru) | 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы | |
| JP2004521908A (ja) | Ｍｍｐ阻害剤としてのトリアゾロ化合物 | |
| EP2099757B1 (en) | Sulfoximines as kinase inhibitors | |
| JP5674828B2 (ja) | Ｐｄｅ１０インヒビターならびに関連する組成物および方法 | |
| EP1652839A2 (en) | Drug efflux pump inhibitor | |
| JP2004523546A5 (enExample) | ||
| US20040204477A1 (en) | Interaction inhibitors of tcf-4 with beta-catenin | |
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| JP2014506599A5 (enExample) | ||
| Chen et al. | A highly enantioselective approach towards 2-substituted 3-bromopyrrolidines | |
| BG107985A (bg) | Производни на заместени триазолдиамини, използвани като инхибитори на киназа | |
| AU2006239418A1 (en) | Novel oxadiazole derivatives and their medical use | |
| JP2007500715A5 (enExample) | ||
| JP2007500716A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| WO2014003153A1 (ja) | 置換アミド化合物 | |
| JP2013506637A5 (enExample) | ||
| EP2107054A1 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| RU2002130245A (ru) | Соли бициклических, n-ацилированных имидазо-3-аминов и имидазо-5-аминов | |
| EP2768809B1 (en) | Pyridine-sulfoximines as tyrosine kinase inhibitors | |
| RU2015123276A (ru) | Соединения замещенного изоксазоламина в качестве ингибиторов стеароил-коа-десатуразы 1 (scd1) | |
| RU2002110282A (ru) | Замещенные в 6-членном кольце бициклические производные имидазо-3-иламина |